カテゴリー： Transparency Market Research, 世界, 部品/材料

小細胞肺がん（SCLC）治療薬の世界市場2023～2031：治療タイプ別、投与経路別

◆英語タイトル：Small Cell Lung Cancer (SCLC) Therapeutics Market (Therapy Type: Targeted Therapy, Immunotherapy, and Chemotherapy; Route of Administration: Oral, Parenteral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが発行した調査報告書（TMR23JUL149）◆商品コード：TMR23JUL149
◆発行会社（リサーチ会社）：Transparency Market Research
◆発行日：2023年4月
◆ページ数：201
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ
◆産業分野：化学＆材料
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社は、世界の小細胞肺がん（SCLC）治療薬市場規模が、2023年の46億ドルから予測期間中、年平均11.9％で成長し、2031年には129億ドルに達すると予測しています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療タイプ別（標的療法、免疫療法、化学療法）分析、薬剤種類別（アテゾリズマブ、デュルバルマブ、ルルビネクテディン、ペンブロリズマブ、その他）分析、投与経路別（経口、非経口、その他）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの情報を掲載しています。なお、当書には、AstraZeneca plc、Dr. Reddy's Laboratories, Inc.、F. Hoffmann La-Roche Ltd.、GSK plc、Jazz Pharmaceuticals plc、Merck & Co., Inc.、Novartis AG、Pfizer Inc.などの企業情報が含まれています。
・序論
・仮定＆調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・世界の小細胞肺がん（SCLC）治療薬市場規模：治療タイプ別
- 標的療法の市場規模
- 免疫療法の市場規模
- 化学療法の市場規模
・世界の小細胞肺がん（SCLC）治療薬市場規模：薬剤種類別
- アテゾリズマブの市場規模
- デュルバルマブの市場規模
- ルルビネクテディンの市場規模
- ペンブロリズマブの市場規模
- その他の市場規模
・世界の小細胞肺がん（SCLC）治療薬市場規模：投与経路別
- 経口剤の市場規模
- 非経口剤の市場規模
- その他投与経路の市場規模
・世界の小細胞肺がん（SCLC）治療薬市場規模：流通チャンネル別
- 病院薬局チャンネルの市場規模
- 小売薬局チャンネルの市場規模
- オンライン薬局チャンネルの市場規模
・世界の小細胞肺がん（SCLC）治療薬市場規模：地域別
- 北米の小細胞肺がん（SCLC）治療薬市場規模
- ヨーロッパの小細胞肺がん（SCLC）治療薬市場規模
- アジア太平洋の小細胞肺がん（SCLC）治療薬市場規模
- 中南米の小細胞肺がん（SCLC）治療薬市場規模
- 中東・アフリカの小細胞肺がん（SCLC）治療薬市場規模
・競争状況

Small Cell Lung Cancer (SCLC) Therapeutics Market – Scope of Report
TMR’s report on the global Small Cell Lung Cancer (SCLC) Therapeutics Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Small Cell Lung Cancer (SCLC) Therapeutics Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Small Cell Lung Cancer (SCLC) Therapeutics Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasmonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.

The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global Small Cell Lung Cancer (SCLC) Therapeutics Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Small Cell Lung Cancer (SCLC) Therapeutics Market profiled in this report.

Key Questions Answered in Global Small Cell Lung Cancer (SCLC) Therapeutics Market Report
• What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
• What are the opportunities in the global Plasmonic Materials market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Small Cell Lung Cancer (SCLC) Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global Small Cell Lung Cancer (SCLC) Therapeutics Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Small Cell Lung Cancer (SCLC) Therapeutics Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.

❖ レポートの目次 ❖

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Small Cell Lung Cancer (SCLC) Therapeutics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Therapy Type Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, 2017 – 2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Disease Prevalence & Incidence Rate globally with key countries
    5.3. Key Industry Events
    5.4. COVID-19 Impact on Industry
6. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Therapy Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Therapy Type, 2017 – 2031
        6.3.1. Targeted Therapy
        6.3.2. Immunotherapy
        6.3.3. Chemotherapy
    6.4. Market Attractiveness, by Therapy Type
7. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Drug Type
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Drug Type, 2017 – 2031
        7.3.1. Atezolizumab
        7.3.2. Durvalumab
        7.3.3. Lurbinectedin
        7.3.4. Pembrolizumab
        7.3.5. Etoposide
        7.3.6. Methotrexate
        7.3.7. Topotecan
        7.3.8. Others
    7.4. Market Attractiveness, by Drug Type
8. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Route of Administration
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Route of Administration, 2017 – 2031
        8.3.1. Oral
        8.3.2. Parenteral
        8.3.3. Others
    8.4. Market Attractiveness, by Route of Administration
9. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Distribution Channel
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by Distribution Channel, 2017 – 2031
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness, by Distribution Channel
10. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Country/Region
11. North America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Therapy Type, 2017 – 2031
        11.2.1. Targeted Therapy
        11.2.2. Immunotherapy
        11.2.3. Chemotherapy
    11.3. Market Value Forecast, by Drug Type, 2017 – 2031
        11.3.1. Atezolizumab
        11.3.2. Durvalumab
        11.3.3. Lurbinectedin
        11.3.4. Pembrolizumab
        11.3.5. Etoposide
        11.3.6. Methotrexate
        11.3.7. Topotecan
        11.3.8. Others
    11.4. Market Value Forecast, by Route of Administration, 2017 – 2031
        11.4.1. Oral
        11.4.2. Parenteral
        11.4.3. Others
    11.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country, 2017 – 2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Therapy Type
        11.7.2. By Drug Type
        11.7.3. By Route of Administration
        11.7.4. By Distribution Channel
        11.7.5. By Country
12. Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Therapy Type, 2017 – 2031
        12.2.1. Targeted Therapy
        12.2.2. Immunotherapy
        12.2.3. Chemotherapy
    12.3. Market Value Forecast, by Drug Type, 2017 – 2031
        12.3.1. Atezolizumab
        12.3.2. Durvalumab
        12.3.3. Lurbinectedin
        12.3.4. Pembrolizumab
        12.3.5. Etoposide
        12.3.6. Methotrexate
        12.3.7. Topotecan
        12.3.8. Others
    12.4. Market Value Forecast, by Route of Administration, 2017 – 2031
        12.4.1. Oral
        12.4.2. Parenteral
        12.4.3. Others
    12.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country, 2017 – 2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Spain
        12.6.5. Italy
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Therapy Type
        12.7.2. By Drug Type
        12.7.3. By Route of Administration
        12.7.4. By Distribution Channel
        12.7.5. By Country
13. Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Therapy Type, 2017 – 2031
        13.2.1. Targeted Therapy
        13.2.2. Immunotherapy
        13.2.3. Chemotherapy
    13.3. Market Value Forecast, by Drug Type, 2017 – 2031
        13.3.1. Atezolizumab
        13.3.2. Durvalumab
        13.3.3. Lurbinectedin
        13.3.4. Pembrolizumab
        13.3.5. Etoposide
        13.3.6. Methotrexate
        13.3.7. Topotecan
        13.3.8. Others
    13.4. Market Value Forecast, by Route of Administration, 2017 – 2031
        13.4.1. Oral
        13.4.2. Parenteral
        13.4.3. Others
    13.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country, 2017 – 2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Therapy Type
        13.7.2. By Drug Type
        13.7.3. By Route of Administration
        13.7.4. By Distribution Channel
        13.7.5. By Country
14. Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Therapy Type, 2017 – 2031
        14.2.1. Targeted Therapy
        14.2.2. Immunotherapy
        14.2.3. Chemotherapy
    14.3. Market Value Forecast, by Drug Type, 2017 – 2031
        14.3.1. Atezolizumab
        14.3.2. Durvalumab
        14.3.3. Lurbinectedin
        14.3.4. Pembrolizumab
        14.3.5. Etoposide
        14.3.6. Methotrexate
        14.3.7. Topotecan
        14.3.8. Others
    14.4. Market Value Forecast, by Route of Administration, 2017 – 2031
        14.4.1. Oral
        14.4.2. Parenteral
        14.4.3. Others
    14.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country, 2017 – 2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Therapy Type
        14.7.2. By Drug Type
        14.7.3. By Route of Administration
        14.7.4. By Distribution Channel
        14.7.5. By Country
15. Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Therapy Type, 2017 – 2031
        15.2.1. Targeted Therapy
        15.2.2. Immunotherapy
        15.2.3. Chemotherapy
    15.3. Market Value Forecast, by Drug Type, 2017 – 2031
        15.3.1. Atezolizumab
        15.3.2. Durvalumab
        15.3.3. Lurbinectedin
        15.3.4. Pembrolizumab
        15.3.5. Etoposide
        15.3.6. Methotrexate
        15.3.7. Topotecan
        15.3.8. Others
    15.4. Market Value Forecast, by Route of Administration, 2017 – 2031
        15.4.1. Oral
        15.4.2. Parenteral
        15.4.3. Others
    15.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
        15.5.1. Hospital Pharmacies
        15.5.2. Retail Pharmacies
        15.5.3. Online Pharmacies
    15.6. Market Value Forecast, by Country, 2017 – 2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Therapy Type
        15.7.2. By Drug Type
        15.7.3. By Route of Administration
        15.7.4. By Distribution Channel
        15.7.5. By Country
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of companies)
    16.2. Market Share Analysis By Company (2021)
    16.3. Company Profiles
        16.3.1. AstraZeneca plc
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Test Type Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Dr. Reddy’s Laboratories, Inc.
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Test Type Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. F. Hoffmann La-Roche Ltd.
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Test Type Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. GSK plc
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Test Type Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Jazz Pharmaceuticals plc
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Test Type Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Merck & Co., Inc.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Test Type Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Novartis AG
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Test Type Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Pfizer Inc.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Test Type Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview

List of Tables

Table 01: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031

Table 02: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 03: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 04: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 05: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 06: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 06: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 07: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031

Table 08: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 09: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 10: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 11: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 12: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031

Table 13: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 14: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 15: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 17: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031

Table 18: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 19: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 20: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 21: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 22: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031

Table 23: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 24: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 25: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 26: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 27: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031

Table 28: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 29: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 30: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 小細胞肺がん（SCLC）治療薬の世界市場2023～2031：治療タイプ別、投与経路別(Small Cell Lung Cancer (SCLC) Therapeutics Market (Therapy Type: Targeted Therapy, Immunotherapy, and Chemotherapy; Route of Administration: Oral, Parenteral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 融合阻害剤の世界市場2022～2031：疾患別、投与経路別
  • カルシウムチャネル遮断薬の世界市場2023～2031：薬剤クラス別、用途別、投与経路別
  • 世界のギランバレー症候群（GBS）市場2023-2031：治療薬別（免疫グロブリン静注、血漿交換、その他）、投与経路別（経口、非経口）
  • 世界の乾癬性関節炎治療薬市場2022年ｰ2031年：薬効クラス別（TNF阻害剤、インターロイキン阻害剤、PDE4阻害剤、その他）、投与経路別
  • 抗感染症薬の世界市場2023～2031：薬剤クラス別、投与経路別

    • ◆H&Iグローバルリサーチのお客様（例）◆